Anebulo Pharmaceuticals (ANEB) Proxy Filing summary

Executive summary

• A special meeting is called to approve a reverse stock split at a ratio between 1-for-2,500 and 1-for-7,500, with the exact ratio set by the Board, as part of a plan to go private and delist from Nasdaq.

• The reverse split aims to reduce the number of record holders below 300, enabling deregistration from the SEC and ending public reporting obligations.

• Stockholders with fewer than the minimum number of shares (2,500–7,500) will be cashed out at $3.50 per share; those with at least the minimum will retain shares post-split.

• The Board and a Special Committee of independent directors unanimously recommend voting in favor, citing cost savings and limited public company benefits.

• Houlihan Capital provided a fairness opinion, concluding the cash-out price is fair to minority, unaffiliated shareholders.

Voting matters and shareholder proposals

• Two proposals: (1) approve the reverse stock split and (2) approve adjournment of the meeting if more votes are needed.

• Approval requires a majority of outstanding shares; major shareholders representing 91.7% have indicated support.

• No appraisal or dissenters' rights are available under Delaware law.

Board of directors and corporate governance

• The Special Committee, composed of independent directors, evaluated strategic alternatives and retained Houlihan Capital for a fairness opinion.

• The Board and Special Committee determined the transaction is in the best interests of all stockholders, including unaffiliated holders.

• No changes to management structure or Board size are planned immediately, but future adjustments may be considered to reduce costs.